Intensive statin treatment
Phase 3Small molecule
Intensive statin treatment is one of 10 small molecule programs targeting Statin. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Statin
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Combination Therapy
Chong Kun Dang PharmaceuticalPhase 3
Somatostatin Analog
UUniversity of Aarhus
Phase 3
Intensive statin treatment
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
Octreotide
Johnson & JohnsonPreclinical
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 1
Bryostatin 1
NNational Cancer Institute (NCI)
Phase 1
Test Drug
Chong Kun Dang PharmaceuticalPreclinical
Reference Drug
Chong Kun Dang PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Randomized1 trial
High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 4·NCT05585151·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intensive statin treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details